Releases - Karo Bio

View:
 

Found press releases

 

ANNUAL GENERAL MEETING 2013 IN KARO BIO AB

STOCKHOLM, Sweden, May 7, 2013 – At today’s Annual General Meeting in Karo Bio the following main resolutions were passed.
The AGM voted in favour of adopting the income statements and balance sheets for the Group and the parent company, and decided that fund at the disposal of the general meeting, amounting to SEK 36,012,880, should be carried forward. Thus, it was resolved that no dividend should be paid for...

INTERIM REPORT JANUARY-MARCH 2013

The January–March period 2013 in brief

· Net sales amounted to MSEK 8.1 (8.3)
· Net loss for the group was MSEK 10.7 (54.0)
· Loss per share was SEK 0.02 (0.14)
· Cash flow from operating activities was MSEK -9.9 (-41.6)
· Cash and cash equivalents and other short-term investments totaled
MSEK 48.0 (117.0) at the end of the period
· The rights issue conducted in 2012 brought a total of MSEK 28.3 net after...

NOMINATION COMMITTEE’s PROPOSALS TO THE ANNUAL GENERAL MEETING 2013

STOCKHOLM, Sweden, April 30, 2013 – The nomination committee for Karo Bio AB (publ) today informed the company about its proposals to the annual general meeting.
Ahead of the annual general meeting 2013, the nomination committee has consisted of Göran Wessman, chairman of the board, representing Mikael Lönn and his own holding (Protem Wessman AB), Jan Lundström, representing Johan Claesson and his own holding,...

KARO BIO PUBLISHES ANNUAL REPORT

Karo Bio’s Annual Report 2012 has been published and is available on the company’s website www.karobio.se.
Karo Bio is a development company without products on the market and the operations are financed partly by revenues from agreements and partly through the company’s financial assets.
In the annual report’s description of the objectives and strategies it is stated that Karo Bio’s goal is to achieve a neutral...

NOTICE OF ANNUAL GENERAL MEETING IN KARO BIO AB (PUBL)

STOCKHOLM, April 4, 2013 – Karo Bio AB (publ). Shareholders in Karo Bio AB (publ) are hereby called to the annual general meeting on May 7, 2013 at 4.00 p.m. in the Lecture Hall, Novum Science Park (4th floor – elevator E), Hälsovägen 7, Huddinge, Sweden.
Right to attend
Entitled to attend the annual general meeting are those who are both registered shareholders in the share register held by Euroclear Sweden AB...

NOMINATING COMMITTEE APPOINTED IN KARO BIO AB

STOCKHOLM, March 15, 2013 - Karo Bio AB (publ). As changes in ownership structure could be expected upon completion of the right issue last year, the Board has considered it prudent to await the outcome before a Nomination Committee was appointed.
In accordance with the principles adopted by the AGM for appointing the Nomination Committee, the following persons have been appointed, together the Chairman of the...

YEAR-END REPORT JANUARY-DECEMBER 2012

The January–December period and the fourth quarter 2012 in brief
•    Net sales increased to MSEK 33.2 (0.0), whereof the fourth quarter increased to MSEK 8.6 (0.0), mainly attributed to the RoRgamma deal with Pfizer
•    Net loss for the group improved to MSEK -98.3 (-226.6), whereof the fourth quarter improved to MSEK -9.0 (-50.6). The net loss was positively impacted by a reversal of provisions of MSEK I.5...

CHANGE OF THE NUMBER OF SHARES AND VOTES IN KARO BIO

STOCKHOLM, January 31, 2013 - Karo Bio AB (publ) today announced that the company’s total number of shares as per January 31, 2013 amounts to 495,947,369 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the rights issue of 108,883,397 shares with preferential right for the company’s shareholders that was announced on October 24, 2012.

For further...

RIGHTS ISSUE IN KARO BIO COMPLETED

Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zeeland, Singapore, South Africa or Switzerland, or within any other jurisdiction in which the distribution of this press release would not comply with applicable laws and regulations. STOCKHOLM, December 18, 2012 – Karo Bio (publ). The rights issue in Karo Bio, with last day...

KARO BIO ANNOUNCES PROSPECTUS FOR THE RIGHTS ISSUE

Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zeeland, Singapore, South Africa or Switzerland, or within any other jurisdiction in which the distribution of this press release would not comply with applicable laws and regulations. STOCKHOLM, 26 November 2012 – Karo Bio AB (publ). Karo Bio hereby announces the publication...

Karo Bio

The mission of Karo Bio is to develop novel pharmaceuticals for treatment of metabolic diseases. The company is in an exciting stage of its development and is transforming from a drug discovery company to a company with ...

View more


  CONTACT  
  • Erika Söderberg Johnson
  • +46 8 608 60 00
  •